Modality
Small Molecule
MOA
WRNi
Target
TNFα
Pathway
Fibrosis
Epilepsy
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
Sep 2017
→ Apr 2031
Phase 2Current
NCT07116897
1,945 pts·Epilepsy
2017-09→2031-04·Terminated
NCT07727959
2,774 pts·Epilepsy
2022-09→2025-05·Terminated
4,719 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-0311mo agoPh3 Readout· Epilepsy
2025-12-094mo agoOrphan Drug· Epilepsy
2031-04-185.0y awayPh3 Readout· Epilepsy
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Termina…
P2/3
Termina…
Catalysts
Ph3 Readout
2025-05-03 · 11mo ago
Epilepsy
Orphan Drug
2025-12-09 · 4mo ago
Epilepsy
Ph3 Readout
2031-04-18 · 5.0y away
Epilepsy
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07116897 | Phase 2/3 | Epilepsy | Terminated | 1945 | LiverFat |
| NCT07727959 | Phase 2/3 | Epilepsy | Terminated | 2774 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα |